This is an aggregated industry headline. Read the full story at PharmaVoice →
Competition is brewing between ADCs and bispecifics
The dueling modalities are each gaining traction in lung cancer. But will they ultimately become allies?
By PharmaVoice
· Jun 11, 2026
· via PharmaVoice
Image: PharmaVoice
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlinePharmaVoice
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansion…
The WeekFierceBiotech ↗
Staring down a $6 billion patent cliff for its prostate cancer drug Xtandi, Astellas aims to counter the inevi…
The WeekBriefing
STAT News spotlighted obesity drugs in development, peptide therapies going mainstream, and a record biotech I…